Exelixis, Inc. $EXEL Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. cut its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 5.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 26,064,571 shares of the biotechnology company’s stock after selling 1,404,523 shares during the period. Vanguard Group Inc. owned about 0.10% of Exelixis worth $1,076,467,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC grew its holdings in shares of Exelixis by 10.3% during the second quarter. AQR Capital Management LLC now owns 7,606,079 shares of the biotechnology company’s stock valued at $335,238,000 after purchasing an additional 712,190 shares during the last quarter. Geode Capital Management LLC increased its position in Exelixis by 0.4% in the second quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock worth $328,196,000 after buying an additional 28,289 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Exelixis by 42.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock valued at $231,951,000 after buying an additional 1,580,567 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Exelixis by 1,230.8% during the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock valued at $131,994,000 after acquiring an additional 2,955,813 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in shares of Exelixis by 120.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock worth $134,306,000 after acquiring an additional 1,665,110 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $43.63 on Friday. The stock has a market cap of $11.33 billion, a price-to-earnings ratio of 15.75, a PEG ratio of 0.98 and a beta of 0.42. Exelixis, Inc. has a 12 month low of $32.38 and a 12 month high of $49.62. The stock’s 50 day moving average price is $43.88 and its 200 day moving average price is $41.22.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The company had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the firm earned $0.55 EPS. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Analysts Set New Price Targets

EXEL has been the topic of several recent research reports. Truist Financial set a $51.00 price objective on shares of Exelixis in a research report on Wednesday, January 14th. Wolfe Research began coverage on shares of Exelixis in a research note on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Oppenheimer reiterated a “market perform” rating and set a $36.00 price objective on shares of Exelixis in a research report on Wednesday, November 5th. Wall Street Zen raised Exelixis from a “buy” rating to a “strong-buy” rating in a report on Sunday. Finally, Royal Bank Of Canada lifted their target price on Exelixis from $45.00 to $46.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.11.

Insider Activity

In other news, CFO Christopher J. Senner sold 34,278 shares of the firm’s stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $43.00, for a total transaction of $1,473,954.00. Following the completion of the transaction, the chief financial officer owned 1,042,579 shares in the company, valued at approximately $44,830,897. This trade represents a 3.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Brenda Hefti sold 18,669 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $821,622.69. Following the completion of the sale, the senior vice president owned 96,512 shares in the company, valued at $4,247,493.12. The trade was a 16.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 285,058 shares of company stock valued at $12,460,245 over the last quarter. Insiders own 2.82% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.